Dr. Omar Sinno, MD, U.S. Medical Lead, Rare Disease at UCB discusses the positive topline results from the Phase 3 RAISE trial evaluating zilucoplan, a self-administered, subcutaneous (SC) peptide inhibitor of complement component 5 (C5 inhibitor), versus placebo in adults with generalized myasthenia gravis (gMG). Alongside zilucoplan, UCB is also investigating whether rozanolixizumab, an SC-infused monoclonal antibody targeting the neonatal Fc receptor (FcRn), could deliver patient value to people living with gMG. UCB is currently the only company investigating two potential treatments with multiple mechanisms of action in gMG. The safety and efficacy of zilucoplan and rozanolixizumab have not been established and are not approved for use in any indication by any regulatory authority worldwide.
Omar Sinno, MD, MBA, is the U.S. Medical Lead, Rare Disease at UCB. In this role, Dr. Sinno is responsible for providing strategic and executional leadership for the company’s growing presence in the rare neuromuscular disease space and commitment to improving awareness and care for people living with severe disease. He received his medical degree from the Loyola University Chicago Stritch School of Medicine and his MBA from the University of Chicago Booth School of Business. Prior to joining UCB, Omar served as Medical Director of AltaThera Pharmaceuticals in Chicago and as Chief Medical Officer of Unite Genomics in San Francisco.